Lallemand probiotic earns additional IBS health claims

28-Feb-2022

“This is the sum of consistent efforts, constant support, and commitment from the regulatory affairs, marketing, clinical and scientific affairs teams,” Solange Henoud, Lallemand Health Solutions

Lallemand Health Solutions has gained an indication for its probiotic strain L. paracasei HA-196 from Health Canada, recognising the strain’s beneficial effects to help support healthy bowel habits in adults with irritable bowel symptoms (IBS), at a daily dose of 10bn CFU.

This claim is an outcome of recent findings in the gut health area, where the ingredient helped to maintain a good quality of life in populations with IBS. The randomised, double-blind, placebo-controlled study performed on 251 North American adults with different IBS subtypes, demonstrated the ingredient’s ability to support quality of life, reduce frequency of bowel movements in IBS-D participants, and increased bowel movement frequency in IBS-C participants.

“Another achievement in the documentation of our strains being acknowledged” said Solange Henoud, Global Regulatory Affairs Director. “This is the sum of consistent efforts, constant support, and commitment from the regulatory affairs, marketing, clinical and scientific affairs teams.”

Sign up for your free email newsletter

The ingredient has also been selected for its complementary action with Biotis GOS to create a bowel support concept. Lallemand Health Solutions and FrieslandCampina Ingredients recently joined forces to launch gut health products combining pre- and probiotics. PRO-Digest Bowel Support contains 10bn CFU of L. paracasei, and has been specifically designed to promote digestive comfort and improve the day-to-day lives of consumers with occasional digestive disturbances.

Featured Companies

See also